Lek, a Sandoz company, receives a certificate of appreciation for the long-term cooperation in practical training of students
Lek, a Sandoz company, understands knowledge transfer and helping young people gain practical experience as a part of its social responsibility. Therefore the company has been cooperating for many years with academic institutions, including the Faculty of Chemistry and Chemical Technology, University of Ljubljana, which in early February awarded the company a certificate of appreciation for the longstanding and extensive collaboration in practical training of students.
On behalf of the company, the certificate of appreciation was accepted by Vojmir Urlep, President of the Board, and Samo Roš, Director of Human Resources and member of the Board.
In the practical training of students it is important to collaborate with companies, therefore at the end of last year, the faculty decided to acknowledge and thank five companies for their longstanding cooperation and offering the largest number of placements to carry out practical work over many years.
»We are aware of the fact that at the faculty we cannot prepare our students for all of the challenges that they will encounter on their career path. However, with practical training as a part of their curriculum we enable them to build on their theoretical knowledge during their studies and gain valuable experience. We proudly note that good practices often continue in the form of bachelor’s, research, master’s or doctoral theses,« says Martina Kastelic Avsec from the Faculty of Chemistry and Chemical Technology, University of Ljubljana. »We are presenting Lek, a Sandoz company, a certificate of appreciation for their longstanding cooperation in the field of practical training of students. We are also expressing our gratitude to all Lek mentors for transferring professional knowledge, encouraging the development of students and guiding them through the work process. We would like to foster such cooperation also in the future.«
A certificate of appreciation was also awarded to companies Krka, Helios TBLUS, Helios and the Clinical Institute for Clinical Chemistry and Biochemistry of University Medical Center Ljubljana.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en/.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz’s portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32